The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up

BACKGROUND: The effectiveness and safety of macitentan, an endothelin-receptor antagonist (ERA) in the treatment of pulmonary arterial hypertension (PAH), has been demonstrated in numerous randomized clinical trials including SERAPHIN, focused on the reduction of morbidity and mortality. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Jariwala, Pankaj, Maturu, Venkata Nagarjuna, Jadhav, Kartik Pandurang, Punjani, Arshad, Boorugu, Harikishan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926235/
https://www.ncbi.nlm.nih.gov/pubmed/34975047
http://dx.doi.org/10.4103/lungindia.lungindia_671_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926235/
https://www.ncbi.nlm.nih.gov/pubmed/34975047
http://dx.doi.org/10.4103/lungindia.lungindia_671_20

Ejemplares similares